Merck's (MRK.US) Keytruda immunotherapy combination has received full FDA approval.
Generated by AI AgentMarket Intel
Thursday, Mar 20, 2025 9:40 am ET1min read
MRK--
The U.S. FDA today (March 20) announced the full approval of Keytruda (pembrolizumab), a Merck & Co.MRK--, Inc. (MRK.US) developed heavyweight PD-1 inhibitor, in combination with trastuzumab, fluoropyrimidine, and platinum chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1). Keytruda previously received FDA accelerated approval for this indication in 2021.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet